Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Wellesley stories

Nov 16, 2026

Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push

Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to expand development of treatments for rare blood cancers known as myeloproliferative neoplasms, its 14th or 15th acquisition of 2026.

Nov 16, 2026·3 sources
00

Top claims

  • ▪Eli Lilly agreed to acquire Wellesley, Massachusetts-based biotech startup Calytrix Bio Inc. for up to $1.5 billion
  • ▪Eli Lilly has pursued company acquisitions throughout 2026 to expand into oncology, hematology, and autoimmune diseases beyond its blockbuster diabetes and weight-loss franchise
  • ▪Existing therapies for myeloproliferative neoplasms include blood transfusions and JAK inhibitor drugs such as Incyte's Jakafi, which manage disease symptoms rather than targeting underlying mutations

Topics

Mergers & acquisitions (M&A)Biotech startupMergers and acquisitionsEli LillyDrug developmentHematology & Blood CancersCancer & OncologyPharmaceutical IndustryRare diseases

Related entities

Myelofibrosis